DiObex, Inc.

Home > Portfolio > DiObex, Inc.

URL: http://www.diobex.com/
Domain: Healthcare
Area: United States

DiObex, Inc. a clinical-stage company based in San Francisco, is developing unique, first-in-class therapies for the critically under-served metabolic disease market. Our pipeline products address the markets for the treatment of type 1 diabetes, type 2 diabetes and its co-morbidities such as hypertension, dyslipidemia and visceral adiposity (often referred to collectively as "metabolic syndrome"). Obesity is an additional therapeutic focus for the company.

Company	DiObex, Inc.

[04/01/2008]

DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society of Clinical Pharmacology and Therapeutics

Data supports potential use of DIO-902 with Atorvastatin.

[03/18/2008]

DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology

Development program for prevention of insulin-induced hypoglycemia in diabetes

[02/05/2008]

DiObex, Inc. to Present at Merrill Lynch Global Healthcare Conference

DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases,

[01/08/2008]

DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia

DiObex, Inc., a privately held biotechnology company developing treatments for metabolic diseases, announced today t...

[10/25/2007]

DiObex Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that Keith A. Vendola, MD, Head of Corporate Development, will delive...

[10/02/2007]

DiObex, Inc. to Present at BIO Investor Forum 2007

DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that CEO David Cory will deliver a corporate presentation at the upcom...

[09/26/2007]

DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug

DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases,...

[06/24/2007]

DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Top Line Data for the Treatment of Type 2 Diabetes Presented at the 67th Annual Scientific Sessions of American Diabetes Association

[04/23/2007]

DiObex Announces The Appointment Of David Cory As Chief Executive Officer

San Francisco, California - April 23, 2007 - DiObex, Inc., a privately held biopharmaceutical company focused on the development of therapeutics to treat metabolic disea...

[03/26/2007]

DiObex Announces Successful Completion Of Phase 2a Trial Of DIO-902, A Novel Cortisol Synthesis Inhibitor For Type 2 Diabetes

SAN FRANCISCO, Calif. - March 26, 2007 - DiObex, Inc., a privately-held biopharmaceutical company focused on the development of therapeutics to treat metabolic diseases, today announced positive phase 2a results for DIO-902, a novel Cortisol S...

Portfolio Companies